Cargando…

Use of Inotropic Agents in Treatment of Systolic Heart Failure

The most common use of inotropes is among hospitalized patients with acute decompensated heart failure, with reduced left ventricular ejection fraction and with signs of end-organ dysfunction in the setting of a low cardiac output. Inotropes can be used in patients with severe systolic heart failure...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tariq, Sohaib, Aronow, Wilbert S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2015
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4691094/ https://www.ncbi.nlm.nih.gov/pubmed/26690127 http://dx.doi.org/10.3390/ijms161226147

Ejemplares similares

Efficacy of the New Inotropic Agent Istaroxime in Acute Heart Failure
por: Forzano, Imma, et al.
Publicado: (2022)

Ambulatory pulmonary artery pressure monitoring in advanced heart failure patients
por: Yandrapalli, Srikanth, et al.
Publicado: (2017)

Comparison of Positive Inotropic Agents in the Management of Acute Decompensated Heart Failure
por: Kelly, Julie, et al.
Publicado: (2020)

Inotropes do not increase mortality in advanced heart failure
por: Guglin, Maya, et al.
Publicado: (2014)

Agents with inotropic properties for the management of acute heart failure syndromes. Traditional agents and beyond
por: Teerlink, John R., et al.
Publicado: (2009)

Update of treatment of heart failure with reduction of left ventricular ejection fraction
por: Aronow, Wilbert S.
Publicado: (2016)

Effects of Widespread Inotrope Use in Acute Heart Failure Patients
por: Kang, Jeehoon, et al.
Publicado: (2018)

Use of levosimendan in acute and advanced heart failure: short review on available real-world data
por: Pashkovetsky, Eugene, et al.
Publicado: (2019)

Why has positive inotropy failed in chronic heart failure? Lessons from prior inotrope trials
por: Ahmad, Tariq, et al.
Publicado: (2019)

Impact of Sacubitril/Valsartan on Patient Outcomes in Heart Failure: Evidence to Date
por: Akbar, Sara, et al.
Publicado: (2020)

Long‐term administration of intravenous inotropes in advanced heart failure
por: Gentile, Piero, et al.
Publicado: (2021)

Advanced heart failure: guideline‐directed medical therapy, diuretics, inotropes, and palliative care
por: Tomasoni, Daniela, et al.
Publicado: (2022)

Advances in systolic heart failure
por: Yuzefpolskaya, Melana, et al.
Publicado: (2010)

Scandinavian SSAI clinical practice guideline on choice of inotropic agent for patients with acute circulatory failure
por: Møller, M. H., et al.
Publicado: (2018)

Inotropes and Inodilators for Acute Heart Failure: Sarcomere Active Drugs in Focus
por: Nagy, László, et al.
Publicado: (2014)

Active State in Heart Muscle : Its delayed onset and modification by inotropic agents
por: Sonnenblick, Edmund H.
Publicado: (1967)

Is Exercise Training Appropriate for Patients With Advanced Heart Failure Receiving Continuous Inotropic Infusion? A Review
por: Amiya, Eisuke, et al.
Publicado: (2018)

On inotropic effects of UTP in the human heart
por: Neumann, J., et al.
Publicado: (2019)

Myocarditis due to systemic lupus erythematosus associated with cardiogenic shock
por: Tariq, Sohaib, et al.
Publicado: (2017)

Prognosis and risk stratification in patients with decompensated heart failure receiving inotropic therapy
por: Gomes, Clara, et al.
Publicado: (2018)

Intermittent inotropic therapy with levosimendan vs. milrinone in advanced heart failure patients
por: Milwidsky, Assi, et al.
Publicado: (2022)

Inotropes in Acute Heart Failure: From Guidelines to Practical Use: Therapeutic Options and Clinical Practice
por: Bistola, Vasiliki, et al.
Publicado: (2019)

6-Nitrodopamine Is the Most Potent Endogenous Positive Inotropic Agent in the Isolated Rat Heart
por: Britto-Júnior, José, et al.
Publicado: (2023)

Vasopressor stays vasopressor and inotrope stays inotrope!
por: Luckner, Günter, et al.
Publicado: (2008)

Genetics and genomics of dilated cardiomyopathy and systolic heart failure
por: Tayal, Upasana, et al.
Publicado: (2017)

Probenecid: An Oral Inotrope for End-Stage Heart Failure in a Case With Myotonic Dystrophy
por: Klein, Evan C., et al.
Publicado: (2019)

Positive inotropic action of insulin on piglet heart.
por: Rieker, R. P., et al.
Publicado: (1975)

Corticosteroids reduce inotrope requirements in hypotensive liver failure
por: Harry, R, et al.
Publicado: (2001)

Vasopressin Is No Inotrope
por: Roeleveld, Peter Paul
Publicado: (2018)

Echocardiographic evaluation of systolic heart failure
por: Lo, Queenie, et al.
Publicado: (2015)

Expected vs Actual Outcomes of Elective Initiation of Inotropic Therapy During Heart Failure Hospitalization
por: Snipelisky, David, et al.
Publicado: (2020)

Hemodynamic effects of inotropic drugs in heart failure: A network meta-analysis of clinical trials
por: Long, Ling, et al.
Publicado: (2019)

Angiotensin receptor neprilysin inhibitor in inotrope dependent heart failure patients: A case series
por: Taghavi, Sepideh, et al.
Publicado: (2020)

Intermittent inotropic support with levosimendan in advanced heart failure as destination therapy: The LEVO‐D registry
por: Dobarro, David, et al.
Publicado: (2023)

Total inotrope exposure score: an extension of the vasoactive inotrope score
por: Bangalore, H, et al.
Publicado: (2015)

The evolution of natriuretic peptide augmentation in management of heart failure and the role of sacubitril/valsartan
por: Yandrapalli, Srikanth, et al.
Publicado: (2017)

Giant myxoma causing heart failure symptoms
por: Chhabra, Amit, et al.
Publicado: (2012)

Renin Activity in Heart Failure with Reduced Systolic Function—New Insights
por: Sullivan, Ryan D., et al.
Publicado: (2019)

Mitochondrial Pathobiology and Metabolic Remodeling in Progression to Overt Systolic Heart Failure
por: Chaanine, Antoine H., et al.
Publicado: (2020)

Atrial fibrillation in patients with systolic heart failure: pathophysiology mechanisms and management
por: Koniari, Ioanna, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_2u5g8ko15nlmcs5o2v5pnloj8g